bioAffinity Technologies, Inc.
22211 West Interstate 10
Suite 1206
San Antonio, TX 78257
United States
210 698 5334
https://www.bioaffinitytech.com
版塊: Healthcare
行業: Diagnostics & Research
全職員工:
高階主管
| 名稱 | 頭銜 | 支付 | 行使價 | 出生年份 |
|---|---|---|---|---|
| Mr. Steven Girgenti | Founder & Executive Chairman of the Board | 113.75k | 無 | 1946 |
| Ms. Maria Zannes J.D. | Founder, President, CEO & Director | 299.17k | 無 | 1956 |
| Mr. Michael Dougherty CPA, M.B.A. | VP & CFO | 238.92k | 無 | 1979 |
| Mr. Xavier T. Reveles M.S. | Chief Operating Officer | 無 | 無 | 1970 |
| Dr. Vivienne I. Rebel M.D., Ph.D. | Executive VP and Chief Medical & Science Officer | 238.39k | 無 | 1966 |
| Mr. Timothy P. Zannes J.D. | Executive VP, Secretary & General Counsel | 無 | 無 | 1953 |
| Ms. Julie Anne Overton | Director of Communications | 無 | 無 | 無 |
| Mr. Dallas J. Coleman | National Director of Sales | 無 | 無 | 無 |
| Dr. William Bauta Ph.D. | Senior Vice President of Therapeutics | 無 | 無 | 無 |
截止 2023年12月31日為止計算的金額，現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 USD。
描述
bioAffinity Technologies, Inc. engages in developing non-invasive diagnostics to detect early-stage lung cancer and other diseases of the lung. It offers CyPath lung, a diagnostic test, for early detection of lung cancer. The company was incorporated in 2014 and is based in San Antonio, Texas.
公司管治
截至 無 止，bioAffinity Technologies, Inc. 的 ISS 管治質素評分為 無。 Pillar 分數正在審核中：無；董事會：無；股東權利：無；現金賠償：無。
企業管治評分的資料提供： Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險，而 10 分表示較高的管治風險。
